Increase/Decrease in Cash: The total change in cash for the company over the given period.
Neumora Therapeutics, Inc. (NMRA) had Increase/Decrease in Cash of $-35.46M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-53.46M |
|
-- |
|
-- |
|
$52.86M |
|
$-52.86M |
|
$-0.56M |
|
$-53.43M |
|
$-53.43M |
|
$-53.46M |
|
$-53.46M |
|
$-53.46M |
|
$-53.46M |
|
$-52.86M |
|
$-52.44M |
|
179.87M |
|
179.87M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$153.43M |
|
$0.03M |
|
$0.44M |
|
$153.88M |
|
$30.11M |
|
$52.96M |
|
$53.08M |
|
$83.20M |
|
$70.68M |
|
$70.68M |
|
$70.68M |
|
182.16M |
|
| Cash Flow Statement Financials | |
$-46.40M |
|
$0.07M |
|
$10.88M |
|
$182.53M |
|
$147.07M |
|
|
Increase/Decrease in Cash |
$-35.46M |
$7.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.09 |
|
-- |
|
-- |
|
0.43 |
|
0.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-46.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-75.63% |
|
-75.63% |
|
-34.74% |
|
-43.24% |
|
$0.39 |
|
$-0.26 |
|
$-0.26 |
|